Antineutrophil Cytoplasmic Antibody (ANCA) Profile

CPT: 83520(x2); 86037(x3)
83520(x2); 86037(x3)83520(x2); 86037(x3)
83520(x2); 86037(x3)83520(x2); 86037(x3)
Updated on 05/8/2022
Print Share


  • PR3-ANCA

Test Includes

Antimyeloperoxidase (MPO) antibodies; antiproteinase 3 (PR3) antibodies; cytoplasmic antineutrophil cytoplasmic antibodies (cANCA); perinuclear antineutrophil cytoplasmic antibodies (pANCA)

Expected Turnaround Time

3 - 7 days

Related Documents

Specimen Requirements




3 mL

Minimum Volume

1.5 mL (Note: This volume does not allow for repeat testing.)


Red-top tube or gel-barrier tube

Storage Instructions

Room temperature

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Hemolysis; lipemia; gross bacterial contamination

Test Details


For diagnosis and monitoring inflammatory activity in primary systemic small vessel vasculitides. The anti-PR3-ANCA EIA is useful for confirming positive ANCA results by IFA, particularly with the cANCA pattern. Presence of anti-PR3 antibodies is highly specific for Wegener granulomatous (WG) disease, for which the sensitivity is reported to be 98%. Levels of anti-PR3 are elevated during active phases of disease and lower during remission. Monitoring anti-PR3 levels, therefore, can aid in disease management.

The anti-MPO-ANCA EIA is useful for confirming positive ANCA results by IFA, particularly with the P-ANCA pattern. Presence of anti-MPO antibodies is highly specific for idiopathic and vasculitis-associated crescentic glomerulonephritis, classic polyarteritis nodosa, Churg-Strauss syndrome, and polyangiitis overlap syndrome without renal involvement. Levels of anti-MPO are elevated during active phases of disease and lower during remission. Therefore, monitoring anti-MPO levels can aid in disease management.


Results of this assay are not diagnostic proof of the presence or absence of disease and should be used in conjunction with clinical findings.


ANCA: indirect fluorescent antibody (IFA); MPO and PR3: enzyme immunoassay (EIA)


De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis. 1995 Mar; 25(3):380-389. 7872315
Gross W, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol. 1995 Jan; 7(1):11-19 (review). 7718417
Jennette JC, Falk RJ. Antineutrophil cytoplasmic antibodies: Discovery, specificity, disease associations and pathogenic potential. Adv Pathol Lab Med. 1995; 8:363-378.
Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999 Apr; 111(4):507-513. 10191771


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
163873 ANCA Panel 163842 Antimyeloperoxidase (MPO) Abs U/mL 46266-3
163873 ANCA Panel 163859 Antiproteinase 3 (PR-3) Abs U/mL 46267-1
163873 ANCA Panel 162400 Cytoplasmic (C-ANCA) titer 14277-8
163873 ANCA Panel 162401 Perinuclear (P-ANCA) titer 14278-6
163873 ANCA Panel 162402 Atypical pANCA titer 49503-6

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at